The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized dose evaluation of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma: Results from RELATIVITY-020.
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics
 
Stéphane Dalle
Employment - Sanofi Pasteur (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pierre Fabre (Inst)
Patents, Royalties, Other Intellectual Property - TRIM24 regulation pending patent (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)
 
Katriina Jalkanen
Employment - Faron Pharmaceuticals (I)
Stock and Other Ownership Interests - Faron Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Bayer (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; Immunocore; Italfarmaco; Lunaphore Technologies; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre; Replimune
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Sofie Wilgenhof
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Paul Lorigan
Stock and Other Ownership Interests - Supportive Care; The Christie Private Care
Honoraria - BMS; Iovance Biotherapeutics; MLA Dx
Consulting or Advisory Role - Bristol-Myers Squibb; Iovance Biotherapeutics; Merck Sharp & Dohme; NeraCare GmbH
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - BMS (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Brigitte Dreno
Consulting or Advisory Role - Almirall; Bristol-Myers Squibb; Pierre Fabre; Roche/Genentech; Sun Pharma
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
 
Andrew Hill
Employment - Tasman Oncology
Stock and Other Ownership Interests - Tasman Oncology
 
Evan Lipson
Stock and Other Ownership Interests - Iovance Biotherapeutics
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; CareDX; HUYA Bioscience International; Immunocore; Instil Bio; IO Biotech; Merck; Merck KGaA; Nektar; Novartis; OncoSec; Pfizer; Rain Therapeutics; Regeneron; Replimune; Sun Pharma; Syneos Health
Research Funding - 1104Health (Inst); Bristol-Myers Squibb (Inst); Haystack Oncology (Inst); Merck (Inst); Regeneron (Inst); Sanofi (Inst)
 
James Larkin
Honoraria - Bristol-Myers Squibb; Cancer Research UK; Eisai; GlaxoSmithKline; Gynavax; Incyte; iOnctura; Merck Serono; Novartis; Pfizer; Roche; touchEXPERTS; touchIME
Consulting or Advisory Role - Apple Tree Partners; Boston Biomedical; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Immunocore; Incyte; iOnctura; Iovance Biotherapeutics; Ipsen; Merck Serono; Novartis; Pfizer; Roche; YKT Corporation
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; ESMO; GlaxoSmithKline; Roche/Genentech
 
Uwe Martens
Stock and Other Ownership Interests - Lilly; Novo Nordisk
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Guardant Health; MSD Oncology; Roche
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Lilly; Pierre Fabre
 
Eva Muñoz Couselo
Honoraria - BMS; Immunocore; MSD; Novartis; Pierre Fabre; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Immunocore; Menarini; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre; Sanofi
 
Julius Strauss
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Diane Wolf
Employment - Bristol-Myers Squibb Norway
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sourav Mukherjee
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sonia Dolfi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Satyendra Suryawanshi
Employment - Bristol Myers Squibb
Leadership - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre; UCB
Consulting or Advisory Role - Bristol Meyer Squib; Iovance Biotherapeutics; MSD Oncology; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Daiichi Sankyo Europe GmbH (Inst); Day One Biopharmaceuticals (Inst); DOT therapeutics (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IFX (Inst); Immunocore (Inst); Incyte (Inst); IO Biotech (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Kinnate Biopharma (Inst); Merck (Inst); Microbiotica (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Sairopa (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre